Caris Life Sciences and Ontada Team Up to Innovate Cancer Research and Precision Medicine

Caris Life Sciences and Ontada Join Forces for Cancer Care Innovation

Caris Life Sciences, recognized as a leading entity in AI TechBio and a pioneer in precision medicine, has officially announced a strategic collaboration with Ontada, a company focused on oncology real-world evidence and innovative healthcare solutions. This partnership heralds a significant advancement in the realm of cancer research, which aims to bolster the development of next-generation oncology therapies.

A Synergy of Innovation

David Spetzler, President of Caris, expressed the commitment both companies share towards advancing cancer care through rigorous scientific approaches. By combining Caris' unmatched expertise in genomic data with Ontada's comprehensive clinical data, the collaboration is set to revolutionize cancer treatment methodologies and enhance patient outcomes.

Spetzler articulated that the collaboration will encompass various strategic pillars aimed at delivering innovative, multimodal data solutions and actionable insights to healthcare professionals. This alignment aims to create a seamless flow of critical information, effectively linking biopharma, research, and patient care to elevate the standards of oncology treatment.

Comprehensive Data Resources

At its core, the collaboration will leverage Caris' extensive molecular database collected from over 6.5 million tests, which generates around 13 quadrillion data points. In conjunction, Ontada brings to the table a formidable repository of real-world oncology data, including records from over 2.4 million cancer patients covering more than 80 different tumor types. Notably, this data is largely sourced from community treatment settings, where about 85% of cancer patients typically receive care, according to the National Cancer Institute.

Christine Davis, President of Ontada, highlighted how this partnership's unique resource empowers life sciences companies to tackle challenging questions in oncology, potentially paving the way for groundbreaking research and advancements in cancer treatment methods. The rapid evolution of oncology necessitates quick insights, and their collaboration is positioned to meet this need.

Bridging Research and Practice

The synergy between Caris and Ontada goes beyond mere data sharing; it is about establishing a streamlined connection between research and clinical application. Together, they aim to facilitate faster access to informed treatment decisions, personalized therapies, and ongoing participation in clinical trials. Dr. James Hamrick, Chairman of the Caris Precision Oncology Alliance, emphasized that this collaboration embodies a transformative approach to oncology care—one that centers around innovation, efficiency, and enhanced patient outcomes.

The evolution of oncology, marked by the continuous integration of clinical practices and real-world evidence, stands to benefit significantly from this alliance. As they bridge the gap between research innovations and practical applications in patient care, the collaboration underscores Caris and Ontada's objectives of advancing precision medicine.

About Caris Life Sciences

Founded with a vision to realize the promise of precision medicine, Caris Life Sciences is at the forefront of healthcare innovation. By employing comprehensive molecular profiling techniques, including Whole Exome and Whole Transcriptome Sequencing, along with cutting-edge AI and machine learning algorithms, Caris has created a robust infrastructure capable of analyzing the complexities of diseases. Their mission is deeply rooted in improving health outcomes and enhancing the quality of life for all patients.

Headquartered in Irving, Texas, Caris Life Sciences operates globally with additional offices located in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland, ensuring that their services reach diverse markets throughout the U.S. and beyond. For more information, visit CarisLifeSciences.com.